Cette équipe de biologistes et de pathologistes de Stanford vient d’identifier une molécule naturelle, qui rivalise avec le ...

C’est un message d’espoir, surtout en regard de l'incidence des actes de maltraitance à l’égard des enfants : l’adversité à l ...

C’est parfois une simple fracture osseuse lors d'un bras de fer qui remet tout en question et va jusqu’à entraîner un ...

ALBANY, New York, 08 mars 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui ...

Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under ...

ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Offering”) for gross proceeds of ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD . Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared ...

Cet essai Arrest, de phase I, mené par des radiooncologues du London Health Sciences Centre Research Institute (LHSCRI) ...

Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq.

About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using ...

First-ever HPV16-positive head and neck cancer Phase 3 clinical trial. PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Bio ...

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink ...